Literature DB >> 16818704

Establishment in severe combined immunodeficiency mice of subrenal capsule xenografts and transplantable tumor lines from a variety of primary human lung cancers: potential models for studying tumor progression-related changes.

Jean-Claude Cutz1, Jun Guan, Jane Bayani, Maisa Yoshimoto, Hui Xue, Margaret Sutcliffe, John English, Julia Flint, Jean LeRiche, John Yee, Jeremy A Squire, Peter W Gout, Stephen Lam, Yu-Zhuo Wang.   

Abstract

PURPOSE: Lung cancer is a biologically diverse disease and relevant models reflecting its diversity would facilitate the improvement of existing therapies. With a view to establishing such models, we developed and evaluated xenografts of a variety of human lung cancers. EXPERIMENTAL
DESIGN: Using nonobese diabetic/severe combined immunodeficiency mice, subrenal capsule xenografts were generated from primary lung cancer tissue, including moderately and poorly differentiated squamous cell carcinoma, adenocarcinoma, adenosquamous carcinoma, small cell carcinoma, large cell undifferentiated carcinoma, and carcinosarcoma. After 4 to 12 weeks, xenografts were harvested for serial transplantation and comparison with the original tissue via histologic, chromosomal, and cytogenetic analyses.
RESULTS: Xenografts were successfully established. H&E staining showed that xenografts retained major histologic features of the original cancers. Immunohistochemistry and fluorescence in situ hybridization confirmed the human origin of the tumor cells and development in xenografts of murine supportive stroma. Four transplantable lines were developed from rapidly growing tumors (>5 generations), i.e., a small cell lung carcinoma, large cell undifferentiated carcinoma, pulmonary carcinosarcoma, and squamous cell carcinoma. Analyses including spectral karyotyping, comparative genomic hybridization, and fluorescence in situ hybridization, revealed that the xenografts were genetically similar to the original tumors, showing chromosomal abnormalities consistent with karyotypic changes reported for lung cancer.
CONCLUSIONS: The subrenal capsule xenograft approach essentially provides a living tumor bank derived from patient material and a means for isolating and expanding specific cell populations. The transplantable tumor lines seem to provide good models for studying various aspects of tumor progression and a platform for developing novel therapeutic regimens, with the possibility of patient-tailored therapies.

Entities:  

Mesh:

Year:  2006        PMID: 16818704     DOI: 10.1158/1078-0432.CCR-06-0252

Source DB:  PubMed          Journal:  Clin Cancer Res        ISSN: 1078-0432            Impact factor:   12.531


  43 in total

Review 1.  New cast for a new era: preclinical cancer drug development revisited.

Authors:  Grit S Herter-Sprie; Andrew L Kung; Kwok-Kin Wong
Journal:  J Clin Invest       Date:  2013-09-03       Impact factor: 14.808

Review 2.  Lung Cancers: Molecular Characterization, Clonal Heterogeneity and Evolution, and Cancer Stem Cells.

Authors:  Ugo Testa; Germana Castelli; Elvira Pelosi
Journal:  Cancers (Basel)       Date:  2018-07-27       Impact factor: 6.639

Review 3.  Patient-derived tumour xenografts as models for oncology drug development.

Authors:  John J Tentler; Aik Choon Tan; Colin D Weekes; Antonio Jimeno; Stephen Leong; Todd M Pitts; John J Arcaroli; Wells A Messersmith; S Gail Eckhardt
Journal:  Nat Rev Clin Oncol       Date:  2012-04-17       Impact factor: 66.675

Review 4.  Patient-derived human tumour tissue xenografts in immunodeficient mice: a systematic review.

Authors:  Ketao Jin; Lisong Teng; Yanping Shen; Kuifeng He; Zhenzhen Xu; Guangliang Li
Journal:  Clin Transl Oncol       Date:  2010-07       Impact factor: 3.405

5.  From sequence to molecular pathology, and a mechanism driving the neuroendocrine phenotype in prostate cancer.

Authors:  Anna V Lapuk; Chunxiao Wu; Alexander W Wyatt; Andrew McPherson; Brian J McConeghy; Sonal Brahmbhatt; Fan Mo; Amina Zoubeidi; Shawn Anderson; Robert H Bell; Anne Haegert; Robert Shukin; Yuzhuo Wang; Ladan Fazli; Antonio Hurtado-Coll; Edward C Jones; Faraz Hach; Fereydoun Hormozdiari; Iman Hajirasouliha; Paul C Boutros; Robert G Bristow; Yongjun Zhao; Marco A Marra; Andrea Fanjul; Christopher A Maher; Arul M Chinnaiyan; Mark A Rubin; Himisha Beltran; S Cenk Sahinalp; Martin E Gleave; Stanislav V Volik; Colin C Collins
Journal:  J Pathol       Date:  2012-07       Impact factor: 7.996

6.  Therapeutic Antibodies Targeting CSF1 Impede Macrophage Recruitment in a Xenograft Model of Tenosynovial Giant Cell Tumor.

Authors:  Hongwei Cheng; Paul W Clarkson; Dongxia Gao; Marina Pacheco; Yuzhuo Wang; Torsten O Nielsen
Journal:  Sarcoma       Date:  2010-10-13

7.  Stability of preclinical models of aggressive renal cell carcinomas.

Authors:  Mariana Varna; Guilhem Bousquet; Irmine Ferreira; Marie Goulard; Morad El-Bouchtaoui; Pierre Mongiat Artus; Jérome Verine; Eric de Kerviler; Lucie Hernandez; Christophe Leboeuf; Bernard Escudier; Luc Legrès; Niclas Setterblad; Hany Soliman; Jean-Paul Feugeas; Anne Janin; Philippe Bertheau
Journal:  Int J Clin Exp Pathol       Date:  2014-05-15

8.  Establishment and characterization of patient tumor-derived head and neck squamous cell carcinoma xenografts.

Authors:  Mukund Seshadri; Mihai Merzianu; Haikuo Tang; Nestor R Rigual; Maureen Sullivan; Thom R Loree; Saurin R Popat; Elizabeth A Repasky; Bonnie L Hylander
Journal:  Cancer Biol Ther       Date:  2009-12-19       Impact factor: 4.742

9.  Tissue-directed Implantation Using Ultrasound Visualization for Development of Biologically Relevant Metastatic Tumor Xenografts.

Authors:  Raelene A VAN Noord; Tina Thomas; Melanie Krook; Sahiti Chukkapalli; Mark J Hoenerhoff; Jonathan R Dillman; Elizabeth R Lawlor; Valerie P Opipari; Erika A Newman
Journal:  In Vivo       Date:  2017 Sep-Oct       Impact factor: 2.155

10.  Oncogene mutations, copy number gains and mutant allele specific imbalance (MASI) frequently occur together in tumor cells.

Authors:  Junichi Soh; Naoki Okumura; William W Lockwood; Hiromasa Yamamoto; Hisayuki Shigematsu; Wei Zhang; Raj Chari; David S Shames; Ximing Tang; Calum MacAulay; Marileila Varella-Garcia; Tõnu Vooder; Ignacio I Wistuba; Stephen Lam; Rolf Brekken; Shinichi Toyooka; John D Minna; Wan L Lam; Adi F Gazdar
Journal:  PLoS One       Date:  2009-10-14       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.